P1, N=19, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial completion date: Aug 2022 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Nov 2023
12 months ago
Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
P1, N=15, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
12 months ago
Trial completion date • Trial primary completion date
P1, N=10, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
over 2 years ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells